Can social security for nucleic acid testing be reimbursed?

Social security for nucleic acid testing cannot be reimbursed. If it is free for all local staff, individual provinces have their own regulations, and you can consult relevant local departments. Take Hunan as an example, there is a clear document notice.

According to the Notice of Hunan Provincial Development and Reform Commission of Hunan Provincial Medical Insurance Bureau on the Temporary Establishment of COVID-19 Nucleic Acid Testing Price Project (No.6 [2020] of Hunan Medical Insurance Bureau), the price project of nucleic acid testing medical service in COVID-19 is temporarily established by the public medical institutions designated for nucleic acid testing in COVID-19, and the charging standard is tentatively set at 40 yuan/person, excluding the reagent fee for nucleic acid testing.

The procurement cost of nucleic acid detection reagents shall be implemented according to the document No.2 of Xiangcaishe [2020]. The overall procurement standard of nucleic acid detection reagents in the whole province shall not be higher than 120 yuan/person, and the required expenses shall be arranged by the finance at the same level, and patients shall not be charged. Third-party testing institutions in COVID-19 of this province carry out COVID-19 nucleic acid testing at a fixed point, and the charging standard is not higher than 160 yuan/person (including all expenses of reagents and consumables), so as to encourage further reduction of the testing price.

During the epidemic period, the "COVID-19 nucleic acid test" expenses incurred by suspected and confirmed patients in COVID-19 in medical institutions with medical insurance agreements can be included in the medical insurance reimbursement, and the "COVID-19 nucleic acid test" expenses incurred during the outpatient investigation of other patients are paid by the patients themselves; During the epidemic period, the expenses of "COVID-19 nucleic acid detection" incurred by medical insurance inpatients were all included in the scope of reimbursement.

Extended data

On June 19, 2020, the Office of the National Medical Insurance Bureau issued the Notice on Further Improving the Detection Ability of COVID-19, which clarified the nucleic acid and antibody detection projects and related consumables carried out in COVID-19, and based on comprehensive consideration of the needs of prevention and control work in novel coronavirus and the payment ability of local medical insurance funds, they were incorporated into provincial medical insurance diagnosis and treatment projects according to procedures, and the payment conditions were determined simultaneously.

According to the notice, COVID-19 has widely carried out online public procurement of testing reagents and encouraged centralized procurement. Public medical institutions shall purchase COVID-19 detection reagents on the provincial centralized procurement platform of pharmaceutical consumables in their provinces. Encourage provincial and regional medical insurance departments to actively explore the centralized procurement of testing reagents in COVID-19.

People's Network-Can the expenses of fever investigation and nucleic acid detection be reimbursed? The official interpretation is here.

People's Network-Incorporate nucleic acid testing into medical insurance according to procedures